Dave Williamson
XMFGreenwave4
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Recent Articles by Dave Williamson
Apr 7, 2017
by Dave Williamson
Why Amarin Is Tanking Post-Approval
Apr 7, 2017
by Dave Williamson
Why Halozyme Is Tanking Hard
Apr 7, 2017
by Dave Williamson
5 Stocks Launching Past a Swooning Dow
Apr 7, 2017
by Dave Williamson
Why the Dow Is Down
Apr 7, 2017
by Dave Williamson
Can Dendreon Be Saved?
Apr 7, 2017
by Dave Williamson
5 Stocks the Dow's Drop Can't Stop
Apr 7, 2017
by Dave Williamson
The Dow Catches Its Breath
Apr 7, 2017
by Dave Williamson
Another Dendreon Earnings Disaster?
Apr 7, 2017
by Dave Williamson
5 Stocks Surging Past the Dow
Apr 7, 2017
by Dave Williamson
Midyear Review: Arena Pharmaceuticals
Apr 7, 2017
by Dave Williamson
5 Surging Health-Care Stocks
Apr 7, 2017
by Dave Williamson
5 Health-Care Stocks Getting Slaughtered
Apr 7, 2017
by Dave Williamson
2 Biotech Surprise Sell-Offs
Apr 7, 2017
by Dave Williamson
Is Regeneron Priced for Perfection?
Apr 7, 2017
by Dave Williamson
Why the Dow Reclaimed 13,000
Apr 7, 2017
by Dave Williamson
Why the Shorts Are Attacking VIVUS
Apr 7, 2017
by Dave Williamson
Big Pharma's Next Big Failure?
Apr 7, 2017
by Dave Williamson
Is This Obamacare's First Victim?
Apr 7, 2017
by Dave Williamson
Big Pharma Bags Its Biotech Prey
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.